trending Market Intelligence /marketintelligence/en/news-insights/trending/mbrcuhmij4rw6qii11z2ya2 content esgSubNav
In This List

Aileron Therapeutics CEO resigns; interim replacement named

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Aileron Therapeutics CEO resigns; interim replacement named

Joseph Yanchik III resigned as president, CEO and director of Aileron Therapeutics Inc.

The clinical-stage biopharmaceutical company named John Longenecker as interim CEO. Longenecker is the founder and president of JPL Biotech, a biopharma/pharmaceutical consulting company.